(Q44124770)

30 November 2017

title

SWOG-9510: evaluation of topotecan in hormone refractory prostate cancer: a Southwest Oncology Group study (English)

1 reference

30 November 2017

2

Catherine M Tangen

1 reference

30 November 2017

Catherine E Klein

1

1 reference

30 November 2017

Thomas J Braun

3

1 reference

30 November 2017

Maha H A Hussain

4

1 reference

30 November 2017

David M Peereboom

5

1 reference

30 November 2017

Craig R Nichols

6

1 reference

30 November 2017

Saul E Rivkin

7

1 reference

30 November 2017

Shaker R Dakhil

8

1 reference

30 November 2017

E David Crawford

9

1 reference

30 November 2017

publication date

1 September 2002

1 reference

30 November 2017

1 reference

30 November 2017

volume

52

1 reference

30 November 2017

issue

4

1 reference

30 November 2017

page(s)

264-268

1 reference

Results of conservative management of clinically localized prostate cancer.

30 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10118

Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10118

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10118

Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10118

Phase I Clinical and Pharmacology Study of Topotecan Given Daily for 5 Consecutive Days to Patients With Advanced Solid Tumors, With Attempt at Dose Intensification Using Recombinant Granulocyte Colony-Stimulating Factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10118

Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10118

Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10118

Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10118

21 January 2018

Identifiers

DOI

10.1002/PROS.10118

1 reference

30 November 2017

1 reference